Chan Mitchell has filed 14 insider transactions across 2 companies since December 2023.
Most recent transaction: a option exercise of 3166 shares of Avalo Therapeutics, Inc. ($AVTX) on March 28, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 28, 2026 | Avalo Therapeutics, Inc. | $AVTX | Chan Mitchell | Not found | M | Restricted Stock Units | 3166 | $0.00 | 3,167.0000 | 18,133,968 | 49.99% | 0.02% |
| March 28, 2026 | Avalo Therapeutics, Inc. | $AVTX | Chan Mitchell | Not found | M | Common Stock | 3166 | $0.00 | 6,333.0000 | 18,133,968 | 99.97% | 0.02% |
| Jan. 6, 2026 | REGENXBIO Inc. | $RGNX | Chan Mitchell | Chief Financial Officer | A | Stock Options (Right to buy) | 39650 | $0.00 | 39,650.0000 | 51,689,000 | 9999.99% | 0.08% |
| Jan. 6, 2026 | REGENXBIO Inc. | $RGNX | Chan Mitchell | Chief Financial Officer | A | Common Stock | 73749 | $0.00 | 127,717.0000 | 51,689,000 | 136.65% | 0.14% |
| Sept. 1, 2025 | REGENXBIO Inc. | $RGNX | Chan Mitchell | Chief Financial Officer | F | Common Stock | 4901 | $8.93 | 53,968.0000 | 49,509,000 | 8.33% | 0.01% |
| June 17, 2025 | Avalo Therapeutics, Inc. | $AVTX | Chan Mitchell | Director | A | Stock Option (Right to Buy) | 20100 | $0.00 | 20,100.0000 | 10,671,934 | 9999.99% | 0.19% |
| March 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | Chan Mitchell | Director | M | Restricted Stock Units | 3167 | $0.00 | 6,333.0000 | 10,671,934 | 33.34% | 0.03% |
| March 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | Chan Mitchell | Director | M | Common Stock | 3167 | $0.00 | 3,167.0000 | 10,671,934 | 9999.99% | 0.03% |
| Jan. 2, 2025 | REGENXBIO Inc. | $RGNX | Chan Mitchell | Chief Financial Officer | A | Stock Options (Right to buy) | 62547 | $0.00 | 62,547.0000 | 49,509,000 | 9999.99% | 0.13% |
| Sept. 16, 2024 | REGENXBIO Inc. | $RGNX | Chan Mitchell | Chief Financial Officer | A | Stock Options (Right to buy) | 289362 | $0.00 | 289,362.0000 | 43,734,000 | 9999.99% | 0.66% |
| Sept. 16, 2024 | REGENXBIO Inc. | $RGNX | Chan Mitchell | Chief Financial Officer | A | Common Stock | 58869 | $0.00 | 58,869.0000 | 43,734,000 | 9999.99% | 0.13% |
| Aug. 13, 2024 | Avalo Therapeutics, Inc. | $AVTX | Chan Mitchell | Director | A | Restricted Stock Units | 9500 | $0.00 | 9,500.0000 | 0 | 9999.99% | 0.00% |
| Aug. 13, 2024 | Avalo Therapeutics, Inc. | $AVTX | Chan Mitchell | Director | A | Stock Option (Right to Buy) | 24600 | $0.00 | 24,600.0000 | 0 | 9999.99% | 0.00% |
| Dec. 20, 2023 | Avalo Therapeutics, Inc. | $AVTX | Chan Mitchell | Director | A | Stock Option (Right to Buy) | 3334 | $0.00 | 3,334.0000 | 0 | 9999.99% | 0.00% |